

Monograph number: 1351.

Title: Bleomycins.

Drug code(s): NSC-125066.

Literature references: A group of related glycopeptide antibiotics. Variations in the terminal amine account for differing activities. Isolated from *Streptomyces verticillus*: Umezawa, *Antimicrob. Ag. Chemother.* **1965**, 1079. Purification and separation into bleomycins A and B and their components: Umezawa *et al.*, *J. Antibiot.* **19**, 200, 210 (1966); T. Takita *et al.*, *ibid.* **21**, 79 (1968); **22**, 237 (1969). Bleomycin A₂ is the main component of the bleomycin employed clinically. Total structure elucidation: T. Takita *et al.*, *ibid.* **25**, 755 (1972). Revised structure: *ibid.* **31**, 801 (1978). Terminal amines: Fujii *et al.*, *ibid.* **26**, 398 (1973). Synthesis of new bleomycins: T. Takita *et al.*, *ibid.* 254. Total synthesis of bleomycin A₂: *ibid.*, *Tetrahedron Letters* **23**, 521 (1982). Improved total synthesis: S. Saito *et al.*, *J. Antibiot.* **36**, 92 (1983). Biosynthesis: Fujii *et al.*, *ibid.* **27**, 73 (1974). Bleomycins are believed to react with DNA and cause strand scission; they have also been shown to have a type of oxygen transferase activity. Mechanism of action studies: R. M. Burger *et al.*, *Life Sci.* **28**, 715 (1981); N. Marugesan *et al.*, *J. Biol. Chem.* **257**, 8600 (1982). Coordination chemistry: J. C. Dabrowiak, *J. Inorg. Biochem.* **13**, 317 (1980). Clinical pharmacology: S. T. Crooke, *Cancer Chemother.* **3**, 343 (1981). Characterization of analogs: N. J. Oppenheimer *et al.*, *J. Biol. Chem.* **257**, 1606 (1982). Reviews: H. Umezawa, *Pure Appl. Chem.* **28**, 665-680 (1971); C. W. Haidle, R. S. Lloyd, *Antibiotics* vol. 5(pt. 2), F. E. Hahn, Ed. (Springer-Verlag, New York, 1979) pp 124-154; H. Umezawa, *Anticancer Agents Based on Natural Product Models*, J. M. Cassady, J. D. Douros, Eds. (Academic Press, New York, 1980) pp 147-166.



Properties: Colorless or yellowish powder which becomes bluish depending on Cu content. Very sol in water, methanol; slightly sol in ethanol. Practically insol in acetone, ethyl acetate, butyl acetate, ether. uv max: 244-248 , 289-294 nm ($E_{1\text{cm}}^{1\%}$ 121-148, 102-121.5) .

UV Maxima: 244-248; 289-294

Derivative: Sulfate,

CAS Registry: [9041-93-4]

Trade name(s): *Blenoxane (Bristol-Myers Squibb) , Bleo (Nippon Kayaku) .*

Derivative: Bleomycin A₂ ,

Molecular Formula: C₅₅H₈₄N₁₇O₂₁S₃ ,

CAS Registry: [11116-31-7]

Additional name(s): *N¹-[3-(dimethylsulfonio)propyl]bleomycinamide.*

Bleomycin A₂

THERAP CAT: Antineoplastic.